"Based in China, with a global outlook | Hybio Pharmaceuticals makes it to the ‘2023 Guangdong Top 500 Manufacturing Enterprises' list."
On November 22nd, under the guidance of the Department of Industry and Information Technology of Guangdong Province, the Development and Reform Commission of Guangdong Province, and the Department of Commerce of Guangdong Province, with strong support from municipal governments, municipal bureaus of industry and information technology, relevant industry associations, and related enterprises, Jinan University’s Industrial and Economic Research Institute, the Guangdong Manufacturing Industry Association, and the Guangdong Development and Reform Research Institute jointly released the “2023 List of the Top 500 Manufacturing Enterprises in Guangdong Province.”
As a leading domestic manufacturer of peptide drugs, Hybio Pharmaceuticals has earned a spot on the list due to its excellent performance in the field of peptides in both domestic and international markets, leveraging years of accumulated research and development, product, and market advantages. This recognition on the list signifies acknowledgment of Hybio Pharmaceuticals’ long-standing efforts and showcases the company’s development vitality. In the future, Hybio Pharmaceuticals will continue to pursue its vision of “continuous innovation, becoming a leader in the peptide industry.” They will also implement an international development strategy of “Based in China, with a global outlook,” contributing to the high-quality development of the manufacturing industry in Guangdong.